The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $3.3 in the prior trading day, Prime Medicine Inc (NASDAQ: PRME) closed at $3.61, up 9.39%. In other words, the price has increased by $9.39 from its previous closing price. On the day, 3.51 million shares were traded. PRME stock price reached its highest trading level at $3.64 during the session, while it also had its lowest trading level at $3.27.
Ratios:
Our goal is to gain a better understanding of PRME by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.61 and its Current Ratio is at 6.61. In the meantime, Its Debt-to-Equity ratio is 0.73 whereas as Long-Term Debt/Eq ratio is at 0.68.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 01 ’25 when GV 2021 GP, L.L.C. bought 1,500,000 shares for $3.30 per share. The transaction valued at 4,950,000 led to the insider holds 3,262,440 shares of the business.
NELSEN ROBERT bought 3,030,300 shares of PRME for $9,999,990 on Aug 01 ’25. The Director now owns 6,230,300 shares after completing the transaction at $3.30 per share. On Aug 01 ’25, another insider, ARCH Venture Partners XII, LLC, who serves as the 10% Owner of the company, bought 3,030,300 shares for $3.30 each. As a result, the insider paid 9,999,990 and bolstered with 6,230,300 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRME now has a Market Capitalization of 651643456 and an Enterprise Value of 543955584. For the stock, the TTM Price-to-Sale (P/S) ratio is 108.97 while its Price-to-Book (P/B) ratio in mrq is 4.02. Its current Enterprise Value per Revenue stands at 91.008 whereas that against EBITDA is -2.764.
Stock Price History:
The Beta on a monthly basis for PRME is 2.74, which has changed by 0.111111164 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, PRME has reached a high of $6.94, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is -24.51%, while the 200-Day Moving Average is calculated to be 14.15%.
Shares Statistics:
The stock has traded on average 3.88M shares per day over the past 3-months and 3443580 shares per day over the last 10 days, according to various share statistics. A total of 180.31M shares are outstanding, with a floating share count of 93.82M. Insiders hold about 48.03% of the company’s shares, while institutions hold 38.15% stake in the company. Shares short for PRME as of 1763078400 were 18603374 with a Short Ratio of 4.79, compared to 1760486400 on 15774156. Therefore, it implies a Short% of Shares Outstanding of 18603374 and a Short% of Float of 16.81.
Earnings Estimates
A comprehensive evaluation of Prime Medicine Inc (PRME) is underway, with the input of 11.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.11 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$1.09 and -$1.41 for the fiscal current year, implying an average EPS of -$1.27. EPS for the following year is -$0.9, with 10.0 analysts recommending between -$0.56 and -$1.39.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for PRME’s current fiscal year. The highest revenue estimate was $13.79M, while the lowest revenue estimate was $3.79M, resulting in an average revenue estimate of $5.7M. In the same quarter a year ago, actual revenue was $2.98M
